Intraarterial Chemotherapy for Liver Metastases.

Surgical Oncology Clinics of North America
Louise C Connell, Nancy E Kemeny

Abstract

Colorectal cancer (CRC) is one of the leading cancers globally in terms of both incidence and cancer-related mortality. Liver metastatic disease is the main prognostic driver for patients with CRC. The management options for liver metastatic CRC continue to evolve, particularly with the incorporation of locoregional therapies into the treatment paradigm. Hepatic arterial infusion (HAI) chemotherapy is one such liver directed approach used with the goal of converting patients to liver resection, reducing the risk of recurrence, treating recurrent disease, and most importantly improving overall survival. This article summarizes the role of HAI chemotherapy in the treatment of liver metastatic CRC.

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P RougierD Gallot
Nov 1, 1990·The British Journal of Surgery·J ScheeleA Altendorf-Hofmann
May 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M Collins
Mar 6, 1996·Journal of the National Cancer Institute·UNKNOWN Meta-Analysis Group in CancerE Levy
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergD D Von Hoff
Feb 27, 2001·Journal of Surgical Oncology·A MuratoreL Capussotti
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N KemenyP Paty
Oct 5, 2001·Journal of the American College of Surgeons·S M WeberL H Blumgart
Feb 8, 2003·Lancet·David J KerrUNKNOWN European Organisation for Research and Treatment of Cancer colorectal cancer study group
Mar 27, 2003·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·B TopalF Penninckx
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 6, 2003·The Oncologist·Adam D Cohen, Nancy E Kemeny
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M G H van RielG Giaccone
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T AndréUNKNOWN GERCOR Group
Feb 18, 2005·The New England Journal of Medicine·Nancy E Kemeny, Mithat Gonen
May 5, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FolprechtC-H Köhne
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy KemenyYuman Fong
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michel DucreuxUNKNOWN gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy E KemenyRobert J Mayer
Mar 9, 2006·Annals of Surgical Oncology·Alice C WeiSteven Gallinger
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James S TomlinsonMichael D'Angelica
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroAimery de Gramont
Dec 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Simone MocellinDonato Nitti
Feb 23, 2008·Cancer Treatment Reviews·Carmelo PozzoNancy E Kemeny
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hanna K SanoffRichard M Goldberg
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy E KemenyMichael D'Angelica
Jun 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W R JarnaginN Kemeny
Apr 9, 2010·The New England Journal of Medicine·Juan ValleUNKNOWN ABC-02 Trial Investigators
Jul 16, 2010·The British Journal of Surgery·E J A MorrisG Poston

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.